Beijing Foyou Pharma (601089.SH): Upadacitinib Extended-Release Tablets Obtain Drug Registration Certificate
Foyou Pharma (601089.SH) announced that recently, the company received the Drug Registration Certificate for Upadacitinib Extended-Release Tablets [specification: 15mg (calculated as CHFNO)] issued by the National Medical Products Administration, approving the production of this drug.
Beijing Foyou Pharma (601089.SH) announced that the company recently received the Drug Registration Certificate issued by the National Medical Products Administration for Upadacitinib Extended-Release Tablets [specification: 15mg (calculated as CHFNO)], approving the production of this drug.
It is understood that this drug is indicated for atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease, non-radiographic axial spondyloarthritis (nr-axSpA), ankylosing spondylitis (AS, radiographic axial spondyloarthritis), and giant cell arteritis. According to relevant national policies, obtaining the Drug Registration Certificate this time is deemed as passing the consistency evaluation.
Related Articles
Pharmaron Beijing (03759) contributes US$10 million to participate in an overseas equity investment fund.
JF SMARTINVEST (09636) repurchased 95,900 shares for HK$2.3275 million on November 6.
WANG ON PPT (01243) Issues Positive Profit Alert, Expects Interim Profit Attributable to Shareholders of Not Less Than HK$150 Million, Turning from Loss to Profit Year-on-Year
Pharmaron Beijing (03759) contributes US$10 million to participate in an overseas equity investment fund.
JF SMARTINVEST (09636) repurchased 95,900 shares for HK$2.3275 million on November 6.
WANG ON PPT (01243) Issues Positive Profit Alert, Expects Interim Profit Attributable to Shareholders of Not Less Than HK$150 Million, Turning from Loss to Profit Year-on-Year
